Pharvaris logo
Pharvaris
PHVS | NASDAQ
Chart Builder DCF Calculator
$32.44
-$0.92 (-2.76%)
At close: Nov 16, 2026, 4:00 PM ET
$32.50
+$0.06 (+0.18%)
After-hours: Nov 16, 2026, 7:30 PM ET

Pharvaris Company Profile

Company profile explained

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Key Executives

Name Position
Berndt Axel Edvard Modig Co-Founder, Chief Executive Officer & Executive Director
David W. Nassif Chief Financial Officer, Chief Legal Officer & Corporate Secretary
Anna Nijdam Head of Strategic Finance & Principal Accounting Officer
Anne Lesage Chief Early Development Officer
Annick Deschoolmeester Chief Human Resources Officer
Maggie Beller VP & Head of Corporate and Investor Communications
Maryann Cimino Director of Corporate Relations
Peng Lu President
Stefan Abele Chief Technology Operations Officer
Wim Souverijns Chief Commercial Officer

Latest SEC Filings

Date Type Title
Oct 13, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 24, 2026 4 Filing
Sep 23, 2026 4 Filing
Sep 21, 2026 4 Filing
Sep 21, 2026 4 Filing
Sep 21, 2026 4 Filing
Sep 21, 2026 4 Filing
Sep 21, 2026 4 Filing
View All SEC Filings ➞
Pharvaris
Pharvaris logo
Country Switzerland
IPO Date Feb 4, 2021
Industry Biotechnology
Sector Healthcare
Employees 148
CEO Berndt Modig

Contact Details

Grafenauweg 8 Zug, ZH 6300 Switzerland

Stock Details

Ticker Symbol PHVS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001830487
CUSIP Number n/a
ISIN Number NL00150005Y4
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.